Neuro Immunoassay Market
Report ID: SQMIG35A3259
Report ID: SQMIG35A3259
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35A3259 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
158
|Figures:
82
Global Neuro Immunoassay Market size was valued at USD 3.2 Billion in 2024 and is poised to grow from USD 3.42 Billion in 2025 to USD 5.88 Billion by 2033, growing at a CAGR of 7.0% during the forecast period (2026-2033).
The neuro immunoassays market is comprised primarily of assays that measure immune and neural biomarkers, which are used for diagnosing and monitoring central nervous system disorders. The increasing incidence of neurodegenerative and neuroinflammatory disorders, as well as the associated clinical and economic burden these diseases place on society is driving the growth of this field. Historically, this market has transitioned from conventional, single-analyte ELISAs to multiplex platforms, and ultimately to ultra-sensitive digital assays (e.g., Simoa) that enable the detection of very low abundance analytes (e.g., neurofilament light and phosphorylated tau) in blood samples.
The primary driver is an urgent clinical need for earlier, minimally invasive diagnostics that inform therapeutic decisions, which has catalyzed investment by diagnostics firms, academic consortia and biopharma partners pursuing disease-modifying therapies.
A key trend driving the global neuro immunoassay sector is technological sensitivity because improved assay performance directly expands clinical applications and market uptake; for instance, detection by platforms such as Simoa has enabled reliable plasma measurement of neurofilament light, which allows neurologists to monitor multiple sclerosis activity and assess concussion recovery without lumbar puncture. As assays prove predictive in Alzheimer’s screening, biopharma sponsors incorporate them into trial enrollment and pharmacodynamic endpoints, creating sustained demand for standardized kits and laboratory services. Consequently regulatory engagement, payer recognition and diagnostics-biomarker partnerships form opportunities for manufacturers to scale, offer new point-of-care formats and integrate assays into routine care pathways.
How is AI Improving Diagnostic Accuracy in the Neuro Immunoassay Market?
Neuro immunoassay diagnostics measure brain specific proteins to detect neurodegeneration and inflammation. The market is moving from single analyte tests to multiplex low abundance assays that need advanced interpretation. Artificial intelligence improves diagnostic accuracy by denoising signals and recognizing complex biomarker patterns across assays and clinical data. AI also standardizes preanalytical quality checks and flags atypical results for review which reduces misclassification and speeds reporting. Combined with more sensitive platforms this makes diagnoses more consistent and actionable in both research and clinical settings.
Bio-Techne in January 2026 introduced ultra sensitive neuro biomarker assays that work well with algorithmic interpretation and automated workflows. AI driven pattern analysis of these assays supports market growth by turning rich multiplex data into clearer clinical decisions and more efficient laboratory throughput.
Market snapshot - (2026-2033)
Global Market Size
USD 3.2 Billion
Largest Segment
Reagents And Kits
Fastest Growth
Analyzers
Growth Rate
7.0% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global neuro immunoassay market is segmented by product type, technology, biomarker type, application, end-user and region. Based on product type, the market is segmented into reagents and kits and analyzers. Based on technology, the market is segmented into radioimmunoassays (RIA), Polymerase chain reaction (PCR), Enzyme-linked immunosorbent assay (ELISA), western blot, rapid tests and enzyme-linked immunospot assay (ELISPOT). Based on biomarker type, the market is segmented into amyloid-beta (Aß), tau protein (p-Tau), alpha-synuclein (a-syn), neurofilament light chain (NfL), autoantibodies, cytokines, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), ubiquitin C-terminal hydrolase L1 (UCH-L1) and brain-derived neurotrophic factor (BDNF).
Based on application, the market is segmented into alzheimer’s disease, parkinson’s disease (PD), huntington’s disease, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Based on end-user, the market is segmented into hospitals, clinics, academic organizations, biopharmaceutical companies, pharmaceutical companies and other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global neuro immunoassay market forecast, reagents and kits segment dominates because these consumables form the operational backbone of neuro immunoassays, enabling routine measurement of disease specific proteins across research and clinical workflows. Reagents are found in abundance; therefore, there exist standardized protocols, lengthened/prolonged periods of procurement as well as compatibility across multiple types of assays. Manufacturer investments into reagent quality and stability and into multiplex panels will further reduce variability in the assays and accelerate the validation of the biomarker increasing the demand for them in laboratories and biopharma studies as well as in the diagnostics environment.
However, analyzers are emerging as the most rapidly expanding area due to automation, integrated multiplexing, and user friendly interfaces that shorten turnaround and enable decentralized testing. Advances in miniaturization and robust calibration software attract clinical adoption and trials, stimulating capital investment and service contracts that open new workflows and opportunities for point of care and high throughput neuro biomarker screening.
Enzyme-Linked Immunosorbent Assay (ELISA) segment dominates because ELISA platforms combine proven analytical reliability with broad adaptability to diverse neuro biomarkers, enabling consistent quantification across discovery and clinical workflows. Through their standardized procedures and established paths for validating processes, technical variation is minimized and regulatory approval is supported. Lab personnel are generally familiar with the usage of ELISA as a routine method for biomarker validation and development of diagnostic assays due to the abundance of reagents available to carry out ELISA tests and ease of automation.
However, Polymerase Chain Reaction (PCR) is emerging as the most rapidly expanding technology owing to its exceptional sensitivity for nucleic acid detection and integration into multiplex and digital platforms. Innovations that enable low input, high precision quantification of disease associated transcripts and pathogen related signals are catalyzing adoption in research and translational studies, creating new opportunities for molecular neurodiagnostics and companion biomarker strategies.
To get detailed segments analysis, Request a Free Sample Report
As per the global neuro immunoassay market analysis, North America leads the due to a confluence of advanced clinical research infrastructure, strong presence of diagnostic and biotech firms, and integrated healthcare systems that facilitate adoption of novel assays. Investment in translational neuroscience is supported by a sound regulatory structure, which leads to quickly being able to validate and commercialize new technologies. There are established methods to receive reimbursement for these technologies through partnerships among academic institutions, hospitals, and industry, which help increase clinician use and increase market access.
There are many clinicians within the region that have trained on various neuroimmunology technologies and organized advocacy groups exist to provide patient education and increased awareness of the need for diagnostic testing through technology developments. Established supply chains and manufacturing capabilities provide the region with resiliency and flexibility to meet ongoing clinical and research needs. A strong funding ecosystem combined with public/private partnerships supports continued development of new technologies, while established clinical trial networks support the establishment of rigorous guidelines for clinical evidence of newer technologies.
Neuro Immunoassay Market in the United States is characterized by extensive research capabilities, a dense network of clinical laboratories, and numerous industry leaders that drive assay innovation. The creation of collaborative ecosystems that connect academia, healthcare institutions, and commercial entities allows for the fast transcription of biomarkers into diagnostic tools. High clinician familiarity with these tools and the presence of institutional pathways for adoption will support the wide-ranging deployment of assays in both neurology and research settings; therefore, the use of clinical guidelines to support clinician integration and long-term patterns of clinical utilization is essential.
Neuro Immunoassay Market in Canada reflects a strong emphasis on collaborative research networks, provincial healthcare structures that enable standardized laboratory practices, and investment in neurodiagnostic capabilities. By providing clinical guidelines, clinician education initiatives, and improving access to diagnostic test development across various care settings through a streamlined procurement process, academic hospitals and public labs that partner with industry, are helping to improve clinician access to the development of assays used in patient diagnosis and research by making it easier for clinicians to integrate the current evidence-based best practice into their local patient care pathway.
Rapid expansion in Europe of the neuro immunoassay market is propelled by concentrated clinical expertise in neurology, widespread deployment of advanced laboratory networks, and strong collaborative frameworks that link research institutions with diagnostic manufacturers. Development of clinical practice guidelines is supported by regulatory harmonization among key global markets, reputable societies of clinical expert members, and encouragement to engage in the development of research strategies, through cross-border consortia, public funding mechanisms and other mechanisms that support the discovery of biomarkers and the validation of assays.
The growing emphasis on personalized neurology and integrated care pathways increases demand for sensitive immunoassays, while the increasing amount of investment and strategic partnerships made by industry players continues to expand the production capacity and distribution capabilities of the clinical immunoassay market, thereby accelerating the growth of this market in a variety of global healthcare systems. The involvement of payers and digital diagnostics enables appropriate reimbursement for implementation into practice, as well as clinical integration for use in clinical settings.
Neuro Immunoassay Market in Germany benefits from a dense clinical research base, integrated university hospital networks, and strong diagnostic manufacturing presence that together enable leadership in assay development and validation. Germany serves as a centre for the clinical use of diagnostic capabilities throughout the region by providing a well-organized clinical trial infrastructure with good collaboration between the testing laboratory and the neurological centres in which the equipment is delivered and tested, along with supportive reimbursement frameworks and professional society members that promote their adoption into routine practice.
Neuro Immunoassay Market in the United Kingdom is driven by dynamic biotech activity, flexible clinical adoption pathways, and strong translational research ecosystems that accelerate assay introduction. Partnerships between academic centers, private laboratories, and health services encourage pragmatic clinical evaluation and scaling. Practitioners' training, as well as training through centers of excellence, aids in the dissemination of best practices and will aid in both expanding clinical usage of these technologies and increasing research involvement.
Neuro Immunoassay Market in France is emerging through focused investments in neurodiagnostics, growing translational research, and strengthening laboratory networks that adapt assays for practice. Diagnostic developers work with national research institutes and teaching hospitals to develop biomarkers and improve how they do their work. Pilot deployments in neurology will be supported by funding and policy measures. Additional support includes increased clinician knowledge and education programs, as well as streamlined laboratory accreditation processes that aid in immunoassay integration into the larger diagnostic pathway.
Asia Pacific is strengthening its role in the neuro immunoassay market through a mix of strategic public and private investments, expanding diagnostic laboratory infrastructure, and growing capabilities in translational neuroscience research. To meet clinical and regulatory standards, regional manufacturers are ramping up the development and localization of assays. Collaboration among global industry partners and academic institutions is escalating, leading to shared technologies, middleware validation at multiple centers of excellence, and better confidence in assay results.
Modernization initiatives across all levels of healthcare and growing clinician awareness of immunoassay testing propel their increased application in tertiary hospitals and specialty clinics. Furthermore, targeted training programs and centralized laboratory networks help standardize testing procedures, while evolving reimbursement discussions and pilot implementations pave the way for broader clinical integration across the region. Government incentives for diagnostics and support for local manufacturing encourage scaling. Digital laboratory systems improve quality control and data sharing for multicenter research, while patient groups and professional societies raise awareness and clinical demand.
Neuro Immunoassay Market in Japan is advancing through strong domestic diagnostic manufacturing, clinical research capabilities, and established laboratory networks that support assay validation and adoption. The collaboration between academic centers and industry is critical to generating the tests that will bring biomarkers to practice. Regulatory bodies are working to streamline evaluation pathways and helped enhance data quality through digital laboratory systems. Increased availability of target clinician training and the development of regional centers has helped allow for the implementation of tests in hospitals and neurology practices.
Neuro Immunoassay Market in South Korea is strengthening through investment in biotech innovation, expanding clinical laboratory capacity, and manufacturers that tailor assays to local needs. Collaboration between public and private entities is supporting translational research and multicenter validation. Automating laboratory processes and managing data digitally will enhance reproducibility of results. Educational programs for neurologists and laboratory staff in addition to pilot implementations at hospitals will promote clinical adoption and increase usage.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advancements In Immunoassay Technologies
Continued improvements in assay sensitivity, specificity, and multiplexing capabilities have expanded the ability to detect neuroimmune biomarkers across diverse sample types and disease states, enabling earlier and more accurate identification of neurological immune responses. Manufacturers' enhancements in reagent chemistry and detection platforms increase clinical confidence and broaden applications in research and diagnostics, encouraging adoption by laboratories and clinicians. This technological progress reduces barriers to use and supports the global neuro immunoassay market growth by enabling new assay formats and workflows suited to neuroinflammatory and neurodegenerative investigations.
Growing Prevalence Of Neurological Disorders
A growing recognition of the role of the immune system in neurological diseases (as evidenced by recent clinical studies & research) has driven an increasing number of clinicians/investigators (and patients) to look for more specific/neurorefined assays to help them better evaluate the presence of inflammation &/or autoantibodies contributing to neurological disorders as well as to aid in diagnosis, monitoring, and guiding treatment decisions. As awareness of the role of the immune system continues to grow, many healthcare providers/laboratories are purchasing assays that have a biological basis of action leading to an increase in the number of neuro immunoassay purchases.
High Development and Validation Costs
Extensive investment required for assay development, clinical validation, and regulatory compliance creates financial and time barriers that limit the number of companies able to bring neuro immunoassays to market. Limited financial resources mean that smaller laboratories and newer manufacturers may not have the ability to bear the burden of extended time frames for product development and/or certification, resulting in less competition and longer wait times for products to become available in the marketplace. This economic constraint results in delayed expansion of assay portfolios and delayed introduction into clinical settings of new diagnostic tools for the neuroimmune system, thereby limiting the breadth of the market even though there is very strong clinical interest in these tools and long-term sustainability problems among smaller companies.
Regulatory Complexity and Approval Delays
The wide range of regulatory requirements in various locations, coupled with the changing nature of diagnostic validation standards, creates uncertainty for developers and hinders the speed with which products can be commercialised, as manufacturers must modify their processes, documentation, and quality systems in order to meet different regulatory requirements. Additionally, the lack of harmonised guidance for neuro immunoassays in terms of both performance criteria and evidence of clinical utility makes it more difficult for companies to make a successful submission to the regulatory agency. Without clear and consistent expectations associated with product submissions, companies may be discouraged from investing in projects, resulting in slower product launches and delays in clinical use of the product, despite demonstrated experimental need.
Request Free Customization of this report to help us to meet your business objectives.
Competitive dynamics in the global neuro immunoassay market outlook are driven by demand for blood based neurodegenerative biomarkers, prompting consolidation and platform partnerships. Firms pursue M&A to acquire antibody and assay expertise for scale for example Fujirebio acquired ADx NeuroSciences in 2022. Startups push platform innovation and licensing deals exemplified by ALZpath licensing pTau217 to Roche and Beckman Coulter and Spear Bio partnering with Bio Techne.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global neuro immunoassay industry is poised for steady expansion as sensitive platforms and growing clinical adoption increase demand. A key driver is advancement in immunoassay technologies that enable detection of low‑abundance biomarkers and support multiplexing. A second driver is the rising prevalence and clinical recognition of neurological disorders that heighten the need for diagnostics. A restraint is the high development and validation of costs that delay product launches and limit smaller players. The dominating region is North America owing to robust research infrastructure and reimbursement frameworks, and the dominating segment is reagents and kits since consumables form the operational backbone of routine testing and biomarker standardization.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 3.2 Billion |
| Market size value in 2033 | USD 5.88 Billion |
| Growth Rate | 7.0% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Neuro Immunoassay Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Neuro Immunoassay Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Neuro Immunoassay Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Neuro Immunoassay Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Neuro Immunoassay Market size was valued at USD 3.2 Billion in 2024 and is poised to grow from USD 3.42 Billion in 2025 to USD 5.88 Billion by 2033, growing at a CAGR of 7.0% during the forecast period (2026-2033).
Competitive dynamics in the global neuro immunoassay market are driven by demand for blood based neurodegenerative biomarkers, prompting consolidation and platform partnerships. Firms pursue M&A to acquire antibody and assay expertise for scale for example Fujirebio acquired ADx NeuroSciences in 2022. Startups push platform innovation and licensing deals exemplified by ALZpath licensing pTau217 to Roche and Beckman Coulter and Spear Bio partnering with Bio Techne. 'Thermo Fisher Scientific Inc.', 'Merck KGaA', 'Bio-Rad Laboratories Inc.', 'GenScript Biotech Corporation', 'Abcam plc', 'BioLegend Inc.', 'Meso Scale Diagnostics LLC', 'Sino Biological Inc.', 'Quanterix Corporation', 'Cusabio Technology LLC', 'OriGene Technologies Inc.', 'Elabscience Biotechnology Inc.', 'RayBiotech Life Inc.', 'Enzo Life Sciences Inc.', 'Rockland Immunochemicals Inc.', 'Assay Genie Ltd.', 'Novus Biologicals LLC', 'Creative Diagnostics', 'MyBioSource Inc.', 'Immuno-Biological Laboratories Co. Ltd.', 'Boster Biological Technology', 'Cloud-Clone Corp.', 'FineTest Biotech Inc.', 'Abbexa Ltd.'
Continued improvements in assay sensitivity, specificity, and multiplexing capabilities have expanded the ability to detect neuroimmune biomarkers across diverse sample types and disease states, enabling earlier and more accurate identification of neurological immune responses. Manufacturers' enhancements in reagent chemistry and detection platforms increase clinical confidence and broaden applications in research and diagnostics, encouraging adoption by laboratories and clinicians. This technological progress reduces barriers to use and supports market expansion by enabling new assay formats and workflows suited to neuroinflammatory and neurodegenerative investigations.
Point Of Care Expansion: Adoption of neuro immunoassays is accelerating beyond central laboratories into clinics and community settings, driven by demand for timely, actionable biomarker information. Simplified platforms and portable instruments enable clinicians to perform testing nearer the patient, improving care pathways and enabling earlier treatment decisions. Integration with clinical workflows and electronic records, coupled with targeted training programs, supports broader implementation. This decentralization enhances access to diagnostic services, fosters collaboration between specialties, and stimulates development of user friendly assays tailored to outpatient environments settings.
As per the global neuro immunoassay market analysis, North America leads the due to a confluence of advanced clinical research infrastructure, strong presence of diagnostic and biotech firms, and integrated healthcare systems that facilitate adoption of novel assays.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
